# Insulet Corporation  Share Price Target ‘$233.07’, now 14.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/insulet-corporation-share-price-target-233.07-now-14.2-upside-potential/4121162168
- Published: 2024-06-25T14:00:50+01:00
- Author: Charlotte Edwards

**Insulet Corporation** with ticker code (PODD) have now 20 analysts in total covering
the stock. The consensus rating is pointing to ‘buy’. The target price High/Low 
ranges between $270.00 and $185.00 calculating the mean target share price we have
$233.07. (at the time of writing). Given that the stocks previous close was at $
204.10 this is indicating there is a potential upside of 14.2%. The 50 day moving
average now sits at $180.02 and the 200 day moving average is $177.77. The company
has a market cap of 14.28B. The current share price for the company is: $203.94 
USD

 The potential market cap would be $16,311,310,763 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 61.43, revenue per share of $25.50
and a 6.74% return on assets.

Insulet Corporation is primarily engaged in the development, manufacture and sale
of its Omnipod System, a continuous insulin delivery system for people with insulin-
dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System(
Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and
the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System 
features a small, lightweight, self-adhesive disposable tubeless Omnipod device (
Pod) that the user fills with insulin and wears directly on the body for up to three
days at a time, which delivers personalized doses of insulin, and the Personal Diabetes
Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with
the user’s personalized insulin-delivery instructions and wirelessly monitors the
Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta
Onpro kit, a delivery system for Amgen’s Neulasta.

Share on: